Literature DB >> 24984791

Certolizumab for the treatment of refractory disseminated pyoderma gangrenosum associated with rheumatoid arthritis.

E Cinotti1, B Labeille, J L Perrot, B Pallot-Prades, F Cambazard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24984791     DOI： 10.1111/ced.12393

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN： 0307-6938            Impact factor:   3.470


× No keyword cloud information.
  5 in total

1.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

Review 2.  Pyoderma gangrenosum: challenges and solutions.

Authors:  Ana Gameiro; Neide Pereira; José Carlos Cardoso; Margarida Gonçalo
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-05-28

3.  Paradoxical Skin Reaction to Certolizumab, an Overlap of Pyoderma Gangrenosum and Psoriasis in a Young Woman Treated for Ankylosing Spondylitis: Case Report with Literature Review.

Authors:  Anna Gawdzik; Małgorzata Ponikowska; Alina Jankowska-Konsur; Zdzisław Woźniak; Joanna Maj; Jacek C Szepietowski
Journal:  Dermatol Ther (Heidelb)       Date:  2020-05-23

4.  Recalcitrant Ulcerative Pyoderma Gangrenosum of the Leg Responsive to Tildrakizumab: A Case Report.

Authors:  Liang Joo Leow; Nicolas Zubrzycki
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-08-23

Review 5.  Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.

Authors:  Carlo Alberto Maronese; Matthew A Pimentel; May M Li; Alex G Ortega-Loayza; Angelo Valerio Marzano; Giovanni Genovese
Journal:  Am J Clin Dermatol       Date:  2022-05-24       Impact factor: 6.233
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.